HC Wainwright Issues Negative Outlook for Compugen Earnings

Compugen Ltd. (NASDAQ:CGEN) – Stock analysts at HC Wainwright dropped their Q2 2026 EPS estimates for Compugen in a note issued to investors on Tuesday, May 19th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of ($0.10) for the quarter, down from their previous estimate of ($0.09). The consensus estimate for Compugen’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Compugen’s Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.38) EPS and FY2027 earnings at ($0.42) EPS.

Other equities analysts have also recently issued research reports about the company. Truist Financial raised Compugen to a “strong-buy” rating in a report on Wednesday, March 25th. Wall Street Zen upgraded Compugen from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Lake Street Capital assumed coverage on Compugen in a research note on Tuesday, April 7th. They set a “buy” rating and a $6.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Compugen Stock Down 1.1%

NASDAQ:CGEN opened at $2.70 on Thursday. Compugen has a 52 week low of $1.29 and a 52 week high of $3.23. The stock’s 50-day moving average price is $2.53 and its 200-day moving average price is $2.01. The stock has a market capitalization of $255.29 million, a PE ratio of 7.30 and a beta of 2.79.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Compugen had a return on equity of 47.72% and a net margin of 47.97%.The firm had revenue of $2.18 million during the quarter, compared to analyst estimates of $1.57 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CGEN. Renaissance Technologies LLC increased its stake in Compugen by 12.1% during the 1st quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock worth $3,478,000 after buying an additional 176,088 shares in the last quarter. State Street Corp raised its holdings in shares of Compugen by 3.9% during the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after acquiring an additional 14,701 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after acquiring an additional 359,785 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Compugen by 10.6% in the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 18,929 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in shares of Compugen by 135.7% in the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 61,202 shares during the last quarter. 12.22% of the stock is owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.